UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of January 2018

 

001-36203

(Commission File Number)

 

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

 

10 Bareket Street

Kiryat Matalon, P.O. Box 7537

Petach-Tikva 4951778, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover

Form 20-F or Form 40-F.

 

Form 20-F þ   Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(7): ____

 

 

 

 

 

 

On January 11, 2018, Can-Fite BioPharma Ltd. issued a press release announcing its near-term milestones for 2018 including events related to the rheumatoid arthritis/psoriasis drug Piclidenoson and the liver disease drug Namodenoson. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. 

 

 1 

 

 

Exhibit Index

 

Exhibit No.   Description
     
99.1   Press Release dated January 11, 2018

 

 2 

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Can-Fite BioPharma Ltd.
     
Date: January 11, 2018 By: /s/ Pnina Fishman
    Pnina Fishman
    Chief Executive Officer

 

 

3